Validating a clinically based MS-MLPA threshold through comparison with Sanger sequencing in glioblastoma patients

Validating a clinically based MS-MLPA threshold through comparison with Sanger sequencing in glioblastoma patients

Abstract Background Glioblastoma is the commonest malignant brain tumor and has a very poor prognosis. Reduced expression of the MGMT gene (10q26.3), influenced primarily by the methylation of two differentially methylated regions (DMR1 and DMR2), is associated with a good response to temozolomide t...

Full description

Saved in:
Bibliographic Details
Main Authors: Halka Lhotska, Karolina Janeckova, Hana Cechova, Jaromir Macoun, Tatiana Aghova, Libuse Lizcova, Karla Svobodova, Lucie Hodanova, Dora Konecna, Jiri Soukup, Filip Kramar, David Netuka, Zuzana Zemanova
Format: Article
Language:English
Published: BMC 2025-01-01
Series:Clinical Epigenetics
Subjects:
Glioblastoma
MGMT
Methylation
MS-MLPA
Sanger sequencing
Stupp protocol
Online Access:https://doi.org/10.1186/s13148-025-01822-2
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s13148-025-01822-2

Similar Items